BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: BioCryst Pharmaceuticals (BCRX) - BioCryst Pharmaceuticals currently holds a Momentum Style Score of B, indicating a favorable momentum characteristic [2] - The company has a Zacks Rank of 1 (Strong Buy), suggesting strong potential for outperformance in the market [3] Performance Metrics - BCRX shares have increased by 1.51% over the past week, while the Zacks Medical - Drugs industry remained flat during the same period [5] - Over the last month, BCRX's price change is 8.96%, outperforming the industry's 3.76% [5] - In the past quarter, BCRX shares have surged by 48.41%, and over the last year, they have gained 66.02%, compared to the S&P 500's increases of 2.37% and 14.4%, respectively [6] Trading Volume - The average 20-day trading volume for BCRX is 4,994,540 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the last two months, 6 earnings estimates for BCRX have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from -$0.06 to $0.16 [9] - For the next fiscal year, 6 estimates have also moved upwards without any downward revisions [9] Conclusion - Considering the positive performance metrics and earnings outlook, BCRX is positioned as a 1 (Strong Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [11]